Comparison · NCT01314911-6d35919c
Oseltamivir vs Placebo: 28-day Mortality
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Oseltamivir vs Placebo: 28-day Mortality. Trial comparisons, record NCT01314911-6d35919c. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01314911-6d35919c
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.0137 | wilson | |
| Risk in group 2 | 0 | 0 | 0.0136 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.0136 | 0.0137 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Oseltamivir | Oseltamivir: Subjects were prescribed Oseltamivir twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg. | 0 | 277 | OG000 |
| Group 2 | Placebo | Placebo: Subjects were prescribed the matching placebo twice daily for 5 days, and each dose consisted of one capsule of placebo. | 0 | 279 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- 28-day Mortality
- Description
- Number of deaths
- Time frame
- From treatment initiation to Day 28
- Population
- The population analyzed is the Intention To Treat (ITT) Population, which included all participants who were randomized properly and who had received at least one dose of study drug.
Source ClinicalTrials.gov
Trial
- Title
- Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
- NCT number
- NCT01314911
- Phases
- NA
- Conditions
- Influenza, Human
- Interventions
- Oseltamivir, Placebo
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2019-02-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01314911?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01314911-6d35919c